The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Gluconeogenesis begins in the mitochondria with the formation of oxaloacetate by the carboxylation of pyruvate. This reaction also requires one molecule of ATP, and is catalyzed by pyruvate carboxylase. This enzyme is stimulated by high levels of acetyl-CoA (produced in β-oxidation in the liver) and inhibited by high levels of ADP and glucose. Oxaloacetate is reduced to malate using NADH, a step required for its transportation out of the mitochondria. Malate is oxidized to oxaloacetate using NAD+ in the cytosol, where the remaining steps of gluconeogenesis take place. Oxaloacetate is decarboxylated and then phosphorylated to form phosphoenolpyruvate using the enzyme PEPCK. A molecule of GTP is hydrolyzed to GDP during this reaction. The next steps in the reaction are the same as reversed glycolysis. However, fructose 1,6-bisphosphatase converts fructose 1,6-bisphosphate to fructose 6-phosphate, using one water molecule and releasing one phosphate (in glycolysis, phosphofructokinase 1 converts F6P and ATP to F1,6BP and ADP). This is also the rate-limiting step of gluconeogenesis. Glucose-6-phosphate is formed from fructose 6-phosphate by phosphoglucoisomerase (the reverse of step 2 in glycolysis). Glucose-6-phosphate can be used in other metabolic pathways or dephosphorylated to free glucose. Whereas free glucose can easily diffuse in and out of the cell, the phosphorylated form (glucose-6-phosphate) is locked in the cell, a mechanism by which intracellular glucose levels are controlled by cells.
RNa + M2+ ⇌ RM+ + Na+ The water coming out of the column is relatively rich in sodium ions and poor in calcium and magnesium which are retained on the column. The column is regenerated by passing a strong solution of sodium chloride through it, so that the resin–sodium complex is again formed on the column. Ion-exchange chromatography utilizes a resin such as chelex 100 in which iminodiacetate residues, attached to a polymer backbone, form chelate complexes of differing strengths with different metal ions, allowing the ions such as Cu2+ and Ni2+ to be separated chromatographically. Another example of complex formation is in chiral chromatography in which is used to separate enantiomers from each other. The stationary phase is itself chiral and forms complexes selectively with the enantiomers. In other types of chromatography with a solid stationary phase, such as thin-layer chromatography the analyte is selectively adsorbed onto the solid. In gas–liquid chromatography (GLC) the stationary phase is a liquid such as polydimethylsiloxane, coated on a glass tube. Separation is achieved because the various components in the gas have different solubility in the stationary phase. GLC can be used to separate literally hundreds of components in a gas mixture such as cigarette smoke or essential oils, such as lavender oil.
0–6 months: 25 μg/d (1000 IU/d) 7–12 months: 38 μg/d (1500 IU/d) 1–3 years: 63 μg/d (2500 IU/d) 4–8 years: 75 μg/d (3000 IU/d) 9+ years: 100 μg/d (4000 IU/d) Pregnant and lactating: 100 μg/d (4000 IU/d) Although in the US the adult UL is set at 4,000 IU/day, over-the-counter products are available at 5,000, 10,000 and even 50,000 IU (the last with directions to take once a week). The percentage of the US population taking over 4,000 IU/day has increased since 1999.
In commenting on humanity's evolution from an ancient primate ancestor, Jung wrote: "We keep forgetting that we are primates and that we have to make allowances for these primitive layers in our psyche." Jung also developed the notion of different evolutionary layers in the psyche in his discussion of fossil hominins such as Pithecanthropus (Homo erectus). As he writes:
MyFerryLink LD Lines SeaFrance Norfolkline Stena Line P&O Stena Line Townsend Thoresen Normandy Ferries Sealink (later Sealink Stena Line) and four companies under the tag: Regie voor Maritiem Transport Stoomvaart Maatschappij Zeeland SNCF British Rail An adjacent freight terminal (with three loading cranes) is scheduled to be repurposed under port redevelopment plans but can currently be used by ships of up to 180 metres (590 ft).
Sources: en.wikipedia.org
== H == Hammock – The hammock was invented by indigenous peoples of the Caribbean and Central America. The word derives from the Taíno word hamaca. Christopher Columbus observed their use in the Bahamas in 1492. Harpoons – the Inuit had developed the harpoon independent of any Old World influences, in order to hunt seals, walrus, and whales. The Inuit of West Greenland called the harpoon maupok. Harpoons enabled the Inuit to hunt large marine mammals from a distance in the umiak and kayak in the open Arctic Ocean. Hockey – both field hockey and ice hockey are based on a game called shinny. This indigenous stickball game was played throughout North America well before the European arrival.
Glutamate synthase facilitates the ammonium assimilation pathway, which follows the enzymes, nitrite reductase and glutamine synthase. An ammonium produced by the nitrite reductase reaction will be incorporated into carbon skeleton backbone by glutamine synthase. Glutamine will be produced because of the introduction of ammonium in the carbon backbone, which can be converted into glutamate by glutamate synthase of another pathway. These processes are common in plant roots because if the nitrogen deficient conditions exist (with access to ammonium and nitrate ions), there will be a first priority of ammonium uptake. The reaction only proceeds in the direction of glutamic acid production: it converts one unit of glutamine and one 2-oxoglutarate into two units of product, using reduced nicotinamide adenine dinucleotide (NADH) as cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. This enzyme participates in glutamate metabolism and nitrogen assimilation. It uses the cofactor, flavin mononucleotide.
=== Mechanistic role in LTP === There is strong evidence that after activation of CaMKII, CaMKII plays a role in the trafficking of AMPA receptors into the membrane and then the PSD of the dendrite. Movement of AMPA receptors increases postsynaptic response to presynaptic depolarization through strengthening the synapses. This produces LTP. Mechanistically, CaMKII phosphorylates AMPA receptors at the P2 serine 831 site. This increases channel conductance of GluA1 subunits of AMPA receptors, which allows AMPA receptors to be more sensitive than normal during LTP. Increased AMPA receptor sensitivity leads to increased synaptic strength. In addition to increasing the channel conductance of GluA1 subunits, CaMKII has also been shown to aid in the process of AMPA receptor exocytosis. Reserve AMPA receptors are embedded in endosomes within the cell. CaMKII can stimulate the endosomes to move to the outer membrane and activate the embedded AMPA receptors. Exocytosis of endosomes enlarges and increases the number of AMPA receptors in the synapse. The greater number of AMPA receptors increases the sensitivity of the synapse to presynaptic depolarization, and generates LTP.
Zverev is a baseline counterpuncher who relies on his massive serve and powerful backhand. He is able to hit strong groundstrokes to open the court, and finish points effectively at the net. Although his height slows him down on the court, it also adds to his reach and gives him the ability to get more balls back in play. Novak Djokovic has commented, "He moves well for his height." His backhand, in particular, is regarded as his strength and one of the best in the game. He can generate a lot of power off it with high accuracy, and his ability to absorb pace makes it one of the best shots in the modern game for both attack and defense. He often uses a semi-open stance and employs a western grip on his forehand. He has a continental-eastern grip on his backhand. Zverev can also slice his backhands that require a low centre of gravity, despite his height. He is often criticized for being too passive in the big moments. With Zverev's height of 1.98 metres (6 ft 6 in), he can generate big serves at 220 kilometres per hour (140 mph) or faster at sharper angles than shorter players. The year Zverev first broke into the top 20, he was still not one of the better servers on tour, ranking just 38th in serve rating. This was well behind him ranking 18th in return rating, showing that his return game was much stronger than his serving. By 2018, he had improved in both categories, ranking 19th in serve rating and 8th in return rating. Zverev excels in particular at hitting a high percentage of first serves in, landing 64.2% in 2018.
Sources: en.wikipedia.org
During the initial outbreak in Wuhan, China, various names were used for the virus; some names used by different sources included "the coronavirus" or "Wuhan coronavirus". In January 2020, the World Health Organization (WHO) recommended "2019 novel coronavirus" (2019-nCoV) as the provisional name for the virus. This was in accordance with WHO's 2015 guidance against using geographical locations, animal species, or groups of people in disease and virus names. On 11 February 2020, the International Committee on Taxonomy of Viruses adopted the official name "severe acute respiratory syndrome coronavirus 2" (SARS‑CoV‑2). To avoid confusion with the disease SARS, the WHO sometimes refers to SARS‑CoV‑2 as "the COVID-19 virus" in public health communications and the name HCoV-19 was included in some research articles. Referring to COVID-19 as the "Wuhan virus" has been described as dangerous by WHO officials, and as xenophobic by many journalists and academics.
Alternatively, in Australia Under the Family Law Act 1975 (Cth), a "stepparent" in relation to a child is interpreted as a person who is not a parent of the child and is, or has been, married to or a de facto partner of a parent of the child, and treats, or at any time while married to or a de facto partner of the parent treated, the child as a member of the family formed with the parent. If one member of the couple has prior children but the couple have another child together, the complex/blended designation replaces the "simple" designation upon the birth of the new child. Any subsequent child born to the couple is a half-sibling of the respective members' prior children.
=== Tumor suppression === It has also been proven to be a tumor suppressor for some tumors. It probably is aided by its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. However it has also been speculated to aid in extravasation in circulating melanoma cells. In case of prostate cancer it has been shown to be expressed in cancer associated stroma but not in normal stroma and has been suggested to be of potential help for cancer specific drug targeting [1].
High fentanyl doses Simultaneous use of methadone Sleep Older age Simultaneous use of CNS depressants like benzodiazepines (i.e. alprazolam, diazepam, clonazepam), barbiturates, alcohol, and inhaled anesthetics Hyperventilation Decreased CO2 levels in the serum Respiratory acidosis Decreased fentanyl clearance from the body Decreased blood flow to the liver Renal insufficiency Sustained release fentanyl preparations, such as patches, may also produce unexpected delayed respiratory depression. The precise reason for sudden respiratory depression is unclear, but there are several hypotheses:
This appeared to be dependent on proteasomal degradation of FoxM1, as expression of a FoxM1 mutant lacking a degron rescued the effects of OGT knockdown. FoxM1 was found not to be directly modified by O-GlcNAc, suggesting that hyper-O-GlcNAcylation of FoxM1 regulators impairs FoxM1 degradation. Targeting OGT also lowered levels of FoxM1-regulated proteins associated with cancer invasion and metastasis (MMP-2 & MMP-9), and angiogenesis (VEGF). O-GlcNAc modification of cofilin S108 has also been reported to be important for breast cancer cell invasion by regulating cofilin subcellular localization in invadopodia.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.